About this trial
Gastrointestinal tumors (esophageal cancer, gastric cancer, colorectal cancer) seriously threaten human health, with a high incidence rate and cancer related hope mortality. Digestive endoscopy is the main method for screening gastrointestinal tumors. Early screening of gastrointestinal tumors can improve the detection of early cancer and improve prognosis. The five-year survival rate of early stage tumors after comprehensive treatment can reach 90%, while the five-year survival rate of late stage tumors is less than 30%. Therefore, the screening of gastrointestinal tumors is very important.
Studies have shown that there are similarities in risk factors for gastrointestinal tumors, such as age, gender, family history, smoking, alcohol consumption, etc. Currently, established digestive malignancies are targeted at a single malignant tumor. At present, there is a lack of understanding of the overall risk factors associated with gastrointestinal tumors and the establishment of relevant risk prediction models.
Therefore, we conducted a prospective, multicenter cross-sectional study to explore the independent risk factors of combined gastrointestinal tumors and establish a risk prediction model for combined screening of gastrointestinal tumors.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Individuals aged 18-80;
Undergoing both gastroscopy and colonoscopy simultaneously.
Disqualifiers
History of esophageal, gastric, or colorectal cancer;
Suspicions of gastrointestinal obstruction or perforation;
History of gastrointestinal tract surgery;
Not suitable for endoscopic examination due to serious diseases or unstable hemodynamics;
Trial population
Continuous patients who underwent both gastroscopy and colonoscopy at the digestive endoscopy center from October 2023 to May 2025
Trial design
Case-control
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Overall detection rate of gastrointestinal cancer
The proportion of at least one type of gastrointestinal malignant tumor detected
Sponsors and contacts
Click on the lead sponsor to view all of their trials.